Effects of oligonucleotide N3′→P5′ thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells

Cancer Research

Volumn 63, Issue 19, 2003, Pages 6187-6194

  Akiyama, Masaharu ^a   Hideshima, Teru ^a   Shammas, Masood A ^a,b   Hayashi, Toshiaki ^a   Hamasaki, Makoto ^a   Tai, Yu Tzu ^a   Richardson, Paul ^a   Gryaznov, Sergei ^c   Munshi, Nikhil C ^a,b   Anderson, Kenneth C ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

^c GERON CORPORATION   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FLUORESCEIN; GRN 163; NUCLEOPROTEIN; OLIGONUCLEOTIDE; OLIGONUCLEOTIDE N3',P5' THIOPHOSPHORAMIDATE; PROTEIN P21; PROTEIN P53; RNA; SYNDECAN 1; TELOMERASE; UNCLASSIFIED DRUG;

ARTICLE; CELL DEATH; CELL DIVISION; CHROMOSOME DAMAGE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME INHIBITION; ENZYME THERAPY; GENE FUSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; INHIBITION KINETICS; LONG TELOMERE; MULTIPLE MYELOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; RNA ANALYSIS; SEQUENCE ANALYSIS; SHORT TELOMERE; TELOMERE;

AMIDES; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME INHIBITORS; HUMANS; MULTIPLE MYELOMA; OLIGONUCLEOTIDES; PHOSPHORIC ACIDS; RNA; TELOMERASE; TELOMERE;

EID: 0141954014     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Blackburn, E. H. Switching and signaling at the telomere. Cell, 106: 661-673, 2001.
2. Kim, S., Kaminker, P., Campisi, J. Telomeres, aging and cancer: in search of a happy ending. Oncogene, 21: 503-511, 2002.
3. Harley, C. B. Telomerase is not an oncogene. Oncogene, 21: 494-502, 2002.
4. Herbert, B. S., Pitts, A. E., Baker, S. I., Hamilton, S. E., Wright, W. E., Shay, J. W., and Corey, D. R. Inhibition of human telomense in immortal human cells leads to progressive telomere shortening and cell death. Proc. Natl. Acad. Sci. USA, 96: 14276-14281, 1999.
5. Hahn, W. C., Stewart, S. A., Brooks, M. W., York, S. G., Eaton, E., Kurachi, A., Beijersbergen, R. L., Knoll, J. H. M., Meyerson, M., and Weinberg, R. A. Inhibition of telomerase limits the growth of human cancer cells. Nat. Med., 5: 1164-1170, 1999.
6. Zhang, X., Mar, V., Zhou, W., Harrington, L., and Robinson, M. O. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Gene Dev., 13: 2388-2399, 1999.
7. Xu, D., Zheng, C., Bergenbrant, S., Holm, G., Bjorkholm, M., Yi, Q., and Gruber, A. Telomerase activity in plasma cell dyscrasias. Br. J. Cancer, 84: 621-625, 2001.
8. Shiratsuchi, M., Muta, K., Abe, Y., Motomura, S., Taguchi, F., Takatsuki, H., Uike, N., Umemura, T., Nawata, H., and Nishimura, J. Clinical significance of telomerase activity in multiple myeloma. Cancer (Phila.), 94: 2232-2238, 2002.
9. Mitsiades, C. S., Mitsiades, N., Poulaki, V., Richardson, P. G., Schlossman, R., Akiyama, M., Chauhan, D., Hideshima, T., Munshi, N., Treon, S. P., and Anderson, K. C. Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple mycloma cells: therapeutic implications. Oncogene, 21: 5673-5683, 2002.
10. Ogata, A., Chauhan, D., Teoh, G., Treon, S. P., Urashima, M., Schlossman, R. L., and Anderson, K. C. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J. Immunol., 159: 2212-2221, 1997.
11. Chauhan, D., Pandey, P., Hideshima, T., Treon, S., Raje, N., Davies, F. E., Shima, Y., Tai, Y. T., Rosen, S., Avraham, S., Kharbanda, S., and Anderson, K. C. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J. Biol. Chem., 275: 27845-27850, 2000.
12. Hideshima, T., Nakamura, N., Chauhan, D., and Anderson, K. C. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene, 20: 5991-6000, 2001.
13. Akiyama, M., Hideshima, T., Hayashi, T., Tai, Y. T., Mitsiades, C. S., Mitsiades, N., Chauhan, D., Richardson, P., Munshi, N. C., and Anderson, K. C. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res., 62: 3876-3882, 2002.
14. Herbert, S. B., Pongracz, K., Shay, J. W., and Gryaznov, S. M. Oligonucleotide N3′→P5′ phosphoramidates as efficient telomerase inhibitors. Oncogene, 21: 638-642, 2002.
15. Pruzan, R., Pongracz, K., Gietzen, K., Wallweber, G., and Gryaznov, S. Allosteric inhibitors of telomerase: oligonucleotide N3′→P5′ phosphoramidates. Nucleic Acids Res., 30: 559-568, 2002.
16. Akiyama, M., Yamada, O., Kanda, N., Akita, S., Kawano, T., Ohno, T., Mizoguchi, H., Eto, Y., Anderson, K. C., and Yamada, H. Telomerase overexpression in K562 leukemia cells protects against apoptosis by serum deprivation and double-stranded DNA break inducing agents, but not against DNA synthesis inhibitors. Cancer Lett., 178: 187-197, 2002.
17. Wang, J., Xie, L. Y., Allan, S., Beach, D., and Hannon, G. J. Myc activates telomerase. Genes Dev., 12: 1769-1774, 1998.
18. Akiyama, M., Hideshima, T., Munshi, N. C., and Anderson, K. C. Telomerase inhibitors as anticancer therapy. Curr. Med. Chem. Anti-Canc Agents, 2: 567-575, 2002.
19. Damm, K., Hemmann, U., Chesa, P. G., Hauel, N., Kauffmann, I., Priepke, H., Niestroj, C., Daiber, C., Enenkel, B., Guilliard, B., Lauritsch, I., Muller, E., Pascolo, E., Sauter, G., Pantic, M., Martens, U. M., Wenz, C., Lingner, J., Kraut, N., Rettig, W. J., and Schnapp, A. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J., 20: 6958-6968, 2001.
20. Wassmann, K., and Benezra, R. Mad2 transiently associates with an APC/ p55 Cdc complex during mitosis. Proc. Natl., Acad. Sci. USA. 95: 11193-11198, 1998.
21. Wang. X., Jin, D. Y., Ng, R. W. M., Feng, H., Wong, Y. C., Cheung, A. L. M., and Tsao, S. W. Significance of MAD2 expression to mitotic checkpoint control in ovarian cancer cells. Cancer Res., 62: 1662-1668, 2002.
22. Wang, X., Jin, D-Y., Wong, H. L., Feng, H., Wong, Y-C., and Tsao, S. W. MAD2-induced sensitization to vincristine is associated with mitotic arrest and Raf/Bcl-2 phosphorylation in nasopharyngeal carcinoma cells. Oncogene, 22: 109-116, 2003.
23. Maser, R. S., and Depinho, R. A. Connecting chromosomes, crisis, and cancer. Science (Wash. DC), 297: 565-569, 2002.
24. Frouin, I., Montecucco, A., Biamonti, G., Hubscher, U., Spadari, S., and Maga, G. Cell cycle-dependent dynamic association of cyclin/Cdk complexes with human DNA replication proteins. EMBO J., 21: 2485-2495, 2002.
25. Uchiumi. F., Watanabe, M., and Tanuma, S. Characterization of telomere-binding activity of replication factor C large subunit p140. Biochem. Biophys. Res. Commun., 258: 482-489, 1999.
26. Itahana, K., Dimri, G., and Campisi, J. Regulation of cellular senescence by p53. Eur. J. Biochem., 268: 2784-2791, 2001.
27. Linda, C., Artandi, S. E., Shen, Q., Tam, A., Lee, S-L., Gottlieb, G. J., Greider, C. W., and Depinho, R. A. p53 deficiency rescues the adverse effects on telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell, 97: 527-538, 1999.
28. Roninson, I. B. Tumor cell senescence in cancer treatment. Cancer Res., 63: 2705-2715, 2003.
29. Vaziri, C., Saxena, S., Jeon, Y., Lee, C., Murata, K., Machida, Y., Wagle, N., Hwang, D. S., and Dutta, A. A. p53-dependent checkpoint pathway prevents replication. Mol. Cell, 11: 997-1008, 2003.
30. Cip1 Cdk inhibitor influences the outcome of p53 response to DNA damage. Nature (Lond.), 419: 729-734, 2002.
31. Wu, K. D., Orme, L. M., Shaughnessy, J., Jr., Jacobson, J., Barlogie, B., and Moore, M. A. S. Telomerase and telomere length in multiple myeloma: correlation with disease heterogeneity, cytogenetic status, and overall survival. Blood, 101: 4982-4989, 2003.